Boundless Life

Stem Cells For Longevity & Performance: The Untold Truth About Domestic vs. International Treatments! with Dr Harry Adelson and Dr Amy Killen

47 snips
Nov 6, 2025
In this engaging discussion, Dr. Harry Adelson, a pioneer in regenerative medicine, and Dr. Amy Killen dive into the transformative world of full-body stem cell therapies. They debunk myths about needing international treatments and highlight domestic options that rival overseas offerings. The pair also discusses the different stem cell sources, safety protocols, and advanced technologies like laser activation that enhance healing. Expect insights on improving longevity, skin health, and even sexual function, while learning how to optimize treatment outcomes!
Ask episode
AI Snips
Chapters
Books
Transcript
Episode notes
INSIGHT

361-HCTP Is The Legal Clinical Pathway

  • There are four regulatory pathways for umbilical cord products; only the 361-HCTP pathway allows clinical injection without a drug trial.
  • 361-HCTP products provide donor screening, sterility, and full traceability through FDA listing.
ANECDOTE

Switch From Autologous After A Happy Patient

  • Harry switched from autologous bone marrow to birth-tissue allogeneic treatments after positive outcomes for a movie stunt-injured patient.
  • The patient regained function and preferred reduced downtime from donor-tissue treatments.
ANECDOTE

Reported Overseas Contamination Harms Patients

  • Harry described serious infections from an overseas clinic that allegedly used contaminated products leading to spinal destruction and kidney failure.
  • He warns that such outcomes are far less likely with properly regulated U.S. manufacturers and facilities.
Get the Snipd Podcast app to discover more snips from this episode
Get the app